Holen Sie sich die Stockscreener-App
4.73
4.15%
-0.19
Schlusskurs vom Vortag:
$4.92
Offen:
$5
24-Stunden-Volumen:
696.14K
Relative Volume:
0.74
Marktkapitalisierung:
$265.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-57.44M
KGV:
-3.5402
EPS:
-1.3361
Netto-Cashflow:
$-56.46M
1W Leistung:
+8.66%
1M Leistung:
-8.07%
6M Leistung:
-36.31%
1J Leistung:
+50.67%
1-Tages-Spanne:
$4.62
$5.005
1-Wochen-Bereich:
$4.41
$5.09
52-Wochen-Spanne:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Firmenname
Protara Therapeutics Inc
Sektor
Branche
Telefon
646-844-0337
Adresse
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.73 | 276.52M | 0 | -57.44M | -56.46M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Fortgesetzt | Guggenheim | Buy |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-17 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-07-29 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
TARA: TARA-002 shows strong efficacy and regulatory momentum in LM and NMIBC, with key H2 catalysts - TradingView
[EFFECT] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study - MSN
Piper Sandler initiates coverage of Protara Therapeutics (TARA) with overweight recommendation - MSN
Protara Therapeutics Inc stock (US87612E1064): analyst optimism contrasts with volatile share price - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $24 to $28 - Moomoo
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Elevance Health (ELV) - The Globe and Mail
Piper Sandler Maintains Protara Therapeutics(TARA.US) With Buy Rating, Announces Target Price $24 - Moomoo
What's Driving Protara's Recent Surge - Kavout
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic MalformationsSlideshow (NASDAQ:TARA) 2026-05-20 - Seeking Alpha
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $25 to $27 - Moomoo
TARA Maintained by Oppenheimer -- Price Target Raised to $28.00 - GuruFocus
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating - Moomoo
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Cantor Fitzgerald reiterates Protara Therapeutics stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - The Manila Times
H.C. Wainwright reiterates Protara stock rating citing LM data By Investing.com - Investing.com Canada
J.P. Morgan Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Protara Therapeutics reports 55% complete response rate in bladder cancer study - MSN
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 - Sahm
protara therapeutics, inc. Earnings dates - RTTNews
Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program - Quiver Quantitative
Protara Therapeutics to Host Virtual Investor Webinar to - GlobeNewswire
Inside Protara’s May 19 webinar on lymphatic malformations and TARA-002 - Stock Titan
Protara Therapeutics Inc stock (US87612E1064): bladder cancer data put small-cap biotech in focus - AD HOC NEWS
H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Protara Therapeutics (TARA) Unveils Promising Phase 2 Trial Resu - GuruFocus
Janus Henderson (TARA) disclosed 5.21M-share, 9.6% stake in Protara - Stock Titan
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study - Benzinga
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Protara reports 12-month data for bladder cancer therapy By Investing.com - Investing.com South Africa
Protara reports 12-month data for bladder cancer therapy - Investing.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC - The Manila Times
Protara Therapeutics announces positive updated 12-month data demonstrating durable responses - marketscreener.com
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses - TradingView
TARA Maintained by JP Morgan -- Price Target Lowered to $26.00 - GuruFocus
Protara Therapeutics 1Q Research and Development Expenses $13.6M >TARA - Moomoo
Protara's TARA-002 Shows Durable Bladder Cancer Response at 12 Months - BriefGlance
Protara Therapeutics stock (US87612E1064): Q1 earnings beat estimates with narrower loss - AD HOC NEWS
A Quick Look at Today's Ratings for Protara Therapeutics(TARA.US), With a Forecast Between $21 to $30 - Moomoo
MSN Money - MSN
Protara Therapeutics, Inc. Q1 2026 Financial Report: Key Updates, Forward-Looking Statements, and Financial Highlights - Minichart
Protara Therapeutics (NASDAQ: TARA) files $300M shelf registration for future offerings - Stock Titan
Protara Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protara Therapeutics (TARA) Prepares for BLA Submission Followin - GuruFocus
Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 for Lymphatic Malformations and NMIBC with BLA Planned for 2027 - Minichart
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Protara Therapeutics 1Q Loss $17.8M >TARA - Moomoo
Protara Therapeutics, Inc. Q1 2026: Net income $(17.8M), EPS $(0.31) — 10-Q Summary - TradingView
Finanzdaten der Protara Therapeutics Inc-Aktie (TARA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):